Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

By D. Cardinale, A. Colombo, R. Torrisi, M. Sandri, M. Civelli, M. Salvatici, Giuseppina Lamantia, N. Colombo, S. Cortinovis, M. Dessanai and 3 more. Journal of Clinical Oncology, 2010

625 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/00a3ac4c5a11d99d8294c0fdd09470cbcc170985

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Oncology

J. Herrmann

Citations in the corpus

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “The benefit of troponins to predict trastuzumab cardiotoxicity is somewhat equivocal and appears to be more helpful in those with prior exposure to anthracyclines.(46,47) The utility of natriuretic peptides (NPs) [B-type NP (BNP), N-terminal pro-BNP (NT-proBNP)] to identify those at risk for anthrac”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “– 113 In patients treated with trastuzumab, particularly when previously exposed to anthracyclines, troponin I elevation can identify patients who will develop cardiac dysfunction and who will not recover despite treatment for HF.(88) New elevation of serum troponin I detected with high-sensitivity ”
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy (2015, neutral): “Hypertension, n (%) 59 (26) 508 (21) 0.”
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, background): “significant reductions in LVEF but increases in LV volumes only in untreated patients.(178) The study, however, lacked placebo administra-”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, background): “In general, the cardiovascular concerns can be summarized in categories related to myocardial dysfunction, vascular disease and VHD. 4.1 Myocardial dysfunction Both paediatric and adult survivors of anthracycline-based chemotherapy have a lifelong risk for the development of LV dysfunction and HF.10”
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. (2014, background): “The initial study in 114 cancer survivors with TnI release demonstrated significant reductions in LVEF but increases in LV volumes only in untreated patients.(178) The study, however, lacked placebo administration, was unblinded, and lacked clinical end points.”
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. (2012, background): “In patients treated with trastuzumab, troponin might help us to distinguish between reversible and irreversible cardiac injury by identifying myocardial cell necrosis [28].”